The ASH meeting included positive early results about a Terns drug for chronic myeloid leukemia and a Kura menin-blocker for ...

Two oral presentations showcase robust efficacy and durable responsesBOSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation ...

NDAA package revives stalled measures on US outbound investment and biotech, signalling Capitol Hill’s hardened stance ...

Data from Structure Therapeutics and WAVE Life Sciences show that threats to Eli Lilly and Novo Nordisk’s dominance in weight ...

Precise Bio Inc., a Greensboro-based clinical-stage regenerative medicine company, has announced the world’s first transplant ...

While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...

As of Monday, December 08, Legend Biotech Corporation’s LEGN share price has dipped by 8.82%, which has investors questioning if this is right time to buy.

The CEO foresees a "snowball effect" of life sciences companies coming to Dallas, but a couple things need to happen first.

PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Michael Breen, CEO of GT Biopharma, said current cancer treatments are 80 years old.

Spyre Therapeutics (SYRE) has strong technical momentum and is trading at a new 52 week high. ・SYRE maintains a 100% “Buy” ...

With the best-selling medication in the world, tirzepatide, and a record-setting $1 trillion valuation to go with it, Eli ...